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New advances in genomic technology are being introduced at a greater speed and are rev-
olutionizing the ﬁeld of genetics for both complex and Mendelian diseases. For instance,
during the past few years, genome-wide association studies (GWAS) have identiﬁed a large
number of signiﬁcant associations between genomic loci and movement disorders such
as Parkinson’s disease and progressive supranuclear palsy. GWAS are carried out through
the use of high-throughput SNP genotyping arrays, which are also used to perform linkage
analyses in families previously considered statistically underpowered for genetic analy-
ses. In inherited movement disorders, using this latter technology, it has repeatedly been
shown that mutations in a single gene can lead to different phenotypes, while the same
clinical entity can be caused by mutations in different genes.This is being highlighted with
the use of next-generation sequencing technologies and leads to the search for genes
or genetic modiﬁers that contribute to the phenotypic expression of movement disorders.
Establishing an accurate genome–epigenome–phenotype relationship is becoming a major
challenge in the post-genomic research that should be facilitated through the implemen-
tation of both functional and cellular analyses. In this review, we summarize the latest
genetic discoveries made by the use of NGS technologies and purpose future directions
and challenges to truly understand the pathophysiology of MDs.
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INTRODUCTION
Movement disorders (MDs) are a group of diseases and syn-
dromes affecting the ability to produce and control movement
Abbreviations: AD, autosomal dominant; AHDS, Allan–Herndon–Dudley syn-
drome; ALS, amyotrophic lateral sclerosis; AP4, adaptor protein complex 4;
AR, autosomal recessive; AT, ataxia telangiectasia; BFIE, benign familial infan-
tile epilepsy; ChAc, chorea-acanthocytosis; CMT, Charcot–Marie–Tooth; CMT1,
Charcot–Marie–Tooth type 1; CMT2, Charcot–Marie–Tooth type 2; CP, cerebral
palsy; DRD, dopa-responsive dystonia; EA, episodic ataxia; ES, exome sequenc-
ing; ET, essential tremor; FA, Friedreich’s ataxia; FAHN, fatty acid hydroxylase-
associated neurodegeneration; FALS, familial ALS; FTD, frontotemporal dementia;
GWAS, genome-wide association studies; HD, Huntington’s disease; HDL2, Hunt-
ington disease-like 2; HDLS, hereditary diffuse leukoencephalopathy with spher-
oids; HSN2C, hereditary sensory neuropathy type IIC; HSP, hereditary spastic
paraplegia; IBMPFD, inclusion body myopathy, Paget disease, and frontotem-
poral dementia; ICCA, infantile convulsions and choreoathetosis syndrome; ID,
intellectual disability; MDs, movement disorders; MJD, Machado–Joseph disease;
MLS, X-linked McLeod syndrome; MSA, multiple system atrophies; MR, mental
retardation; NA, neuroacanthocytosis; NGS, next-generation sequencing; NSID,
non-syndromic ID; PD, Parkinson’s disease; PED, paroxysmal exercise-induced
dyskinesias; PGD, progressive generalized dystonia; PKAN, pantothenate kinase-
associated neurodegeneration; PKC, paroxysmal kinesigenic choreoathetosis; PKD,
paroxysmal kinesigenic dyskinesias; PMD, Pelizaeus–Merzbacher disease; PMLD,
Pelizaeus–Merzbacher-like disease; PNKD,Paroxysmal non-kinesigenic dyskinesias;
PSP, progressive supranuclear palsy; RLS, restless legs syndrome; SALS, sporadic
ALS; SCA, spinocerebellar ataxia; SPG, spastic paraplegia; TR, targeted resequenc-
ing; TS–CTD, Tourette syndrome/chronic tic disorder; TS, Tourette’s syndrome;
WD, Wilson disease; WGS, whole-genome sequencing; XLD, X-linked dominant;
XLR, X-linked recessive.
and are often accompanied by secondary clinical presentations
such as seizures, cognitive deﬁcits, autoimmune deﬁciencies, and
psychiatric symptoms, among others, causing major difﬁculties
in diagnosis and treatment. MDs comprise the following clinical
conditions: ataxia, dystonia, essential tremor (ET), Huntington’s
disease (HD), multiple system atrophies (MSA), Parkinson’s dis-
ease (PD), progressive supranuclear palsy (PSP), restless legs syn-
drome (RLS), tics, Tourette’s syndrome (TS), and Wilson disease
(WD). MDs are classiﬁed as monogenic (Mendelian) or multifac-
torial or polygenic (Complex). However,mutations in knownMD
genes account for only a small percentage of cases, indicating that
more genes and higher-risk alleles await discovery (Kompoliti and
Verhagen, 2010).
Although linkage analysis along with candidate gene screening
was traditionally the preferredmethod for gene discovery in inher-
itedMDs (Paisan-Ruiz et al., 2004, 2005), these are not appropriate
for families with largely reduced penetrance or reduced number
of affected individuals. And even though there has been con-
siderable success in identifying genetic risk factors for PD and
PSP through the application of genome-wide association studies
(GWAS; Simon-Sanchez et al., 2009; Hamza et al., 2010; Hoglinger
et al., 2011), a detailed mapping through targeted resequencing
(TR) is still required to further identify both high-risk alleles and
haplotypes (Tucci et al., 2010; Freedman et al., 2011). By contrast,
next-generation sequencing (NGS) technologies, such as exome
sequencing (ES) and whole-genome sequencing (WGS), enable
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respectively a complete scan resolution of the entire both exome
and genome, allowing a rapid identiﬁcation of disease-causing
mutations and higher-risk alleles. This has already been evidenced
in rare Mendelian diseases where large sample sizes are difﬁcult to
gather (Ng et al., 2009, 2010), and in families previously deemed
statistically insufﬁcient for positional cloning (Bilguvar et al., 2010;
Marti-Masso et al., 2012). Likewise, de novo pathogenic mutations
have recently been identiﬁed in autism spectrum disorders by per-
forming trio-based ES in only 20 sporadic cases (O’Roak et al.,
2011). In conclusion, NGS is an ideal approach to identify causal
alleles for inherited MDs and its application will increase the can-
didate gene list associated with MDs, facilitating the subsequent
diagnosis and understanding of the disease process (Singleton,
2011).
In this review, we ﬁrst describe the phenotypic spectrum asso-
ciated withMDs and second summarize the novel genetic ﬁndings
achieved by the use of NGS in MDs. The genetic contribution of
MDs is expanding by the discovery of novel genes and the associ-
ation of novel neurological phenotypes to already known disease
genes.
MOVEMENT DISORDER PHENOTYPES IN WHICH NGS HAS
BEEN PERFORMED
Below the phenotypes and genetic backgrounds of some inher-
ited MDs in which NGS technologies have been employed are
described. Phenotypes are listed in alphabetical order.
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative dis-
ease that controls the voluntary muscle movement. Because it is
sometimes accompanied by PD and related disorders and some
MDs genes can also cause ALS (Bosco et al., 2011), we decided
to include it here. ALS is characterized by upper and lower motor
neuron dysfunction resulting in progressive paralysis generally fol-
lowed by death due to respiratory failure (Johnston et al., 2006;
Johnson et al., 2010). The majority of ALS is sporadic (∼90%),
and the clinical features of familial ALS (FALS) and sporadic ALS
(SALS) are virtually indistinguishable, aside from a slightly earlier
age at onset of FALS. Even though all FALS genes have also been
implicated in SALS, these only account for a small proportion of
cases, leaving much of the genetics of this disorder to be discov-
ered (Andersen andAl-Chalabi, 2011). SomeALS-associated genes
may also cause other disorders, such as frontotemporal dementia
(FTD), cerebellar ataxia, motor neuropathies, hereditary spastic
paraplegia (HSP), and Parkinsonism.
Ataxia describes a lack of muscle coordination during volun-
tary movements usually due to pathology in the cerebellum and
its connections, such as spinocerebellar and pontocerebellar path-
ways. Although it is a neurological symptom, there are several
inherited disorders that are due to this unsteady movement of
gait and limbs, including Friedreich’s ataxia (FA), spinocerebellar
ataxia (SCA), episodic ataxia (EA), ataxia telangiectasia (AT), and
Machado–Josephdisease (MJD).Ataxias canpresent as sporadic or
hereditary and are divided into ﬁve main categories: mitochondr-
ial,metabolic, defective DNA repair, abnormal protein folding and
degradation, and channelopathies. Based on neurological exami-
nation, ataxias can be broadly classiﬁed into pure cerebellar ataxias
and those inwhich additional neurological deﬁcits are also present.
Most of the ataxias are labeled with the term SCA followed by a
number to denote the distinct locus. At present, there are over 30
SCA loci and at least 17 disease-related genes identiﬁed (Filla and
De Michele, 2012; Subramony, 2012a,b).
Cerebral palsies (CPs) comprise a heterogeneous group of neu-
rodevelopmental disorders characterized by motor and postural
impairments (Pakula et al., 2009). CP is classiﬁed according to
the movement disorder observed as spastic, ataxic, dystonic, or
athetoid, and according to the limbs affected asmonoplegic, hemi-
plegic, diplegic, or quadriplegic (Moreno-De-Luca et al., 2012).
Furthermore, CP is often associated with other neurological com-
plications such as intellectual disability (ID), psychosocial disor-
ders, and seizure disorders, making diagnosis and management of
symptoms difﬁcult (Aisen et al., 2011).
Charcot–Marie–Tooth (CMT) disease is the most common
inheritedneurological disease characterized bydistalmuscleweak-
ness and atrophy (Weedon et al., 2011), and sometimes it occurs
with sensory loss, depressed tendon reﬂexes, and pes cavus (highly
arched feet). There are two main forms of CMT: CMT1 or type
1 that causes demyelination and CMT2 or type 2 that affects
nerve axons. CMT is quite genetically heterogeneous, with over
40 disease-associated loci identiﬁed, and presents with intra-
familial phenotypic variability (Del Bo et al., 2006), making tradi-
tional screening techniques time consuming and genetic diagnosis
difﬁcult.
Dystonias comprise a clinically and genetically heterogeneous
group of MDs characterized by involuntary sustained muscu-
lar contractions affecting one or more sites of the body that
produce abnormal postures and repetitive movements. They are
classiﬁed according their etiology as primary when dystonia is
the sole manifestation or secondary when it is accompanied by
other neurological conditions, and according to the affected mus-
cle groups’distribution as focal, segmental,multifocal, generalized,
and hemidystonias. The most common type of primary dystonia
is primary torsion dystonia,which is caused bymutations in either
DYT1 or DYT6 genes (Ozelius et al., 2011). However, even though
there are more than 20 loci associated with dystonia, most cases
are idiopathic and all familial forms present with reduced pene-
trance, making traditional linkage analyses inaccurate (Fuchs and
Ozelius, 2011).
Fatty acid hydroxylase-associated neurodegeneration (FAHN) is
caused by a deﬁciency of fatty acid 2-hydroxylase (FA2H; Kruer
et al., 2010). FA2H pathogenic mutations were ﬁrst described
in families with leukodystrophy, spastic paraplegia (SPG), and
dystonia (Edvardson et al., 2008), but later in families with
complex SPG (SPG35) and neurodegeneration with brain iron
accumulation (NBIA; Dick et al., 2010; Kruer et al., 2010).
NBIA is characterized by progressive extrapyramidal deteriora-
tion and high brain iron deposition,most consistently in the basal
ganglia.
Leukoencephalopathies are white matter diseases, in which
a movement dysfunction is often a symptom. Sensory, behav-
ioral, and cognitive deﬁcits are also common. For instance,
hereditary diffuse leukoencephalopathy with spheroids (HDLS)
is associated with variable behavioral, cognitive, and motor dys-
function (Rademakers et al., 2011). Clinically, it is difﬁcult to
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diagnose because it often presents with intra-familial hetero-
geneity and a ﬁrm diagnosis often occurs post-mortem (Baba
et al., 2006). Pelizaeus–Merzbacher disease (PMD) is an X-
linked hypomyelinating leukodystrophy, manifested as impaired
motor development followed by ataxia, dystonia, dysarthria, and
progressive spasticity (Vaurs-Barriere et al., 2009).
Parkinson’s disease is the third most common neurodegenera-
tive disorder, behindAlzheimer’s disease and ET, affecting approx-
imately 1–2% of the population above the age of 65, and whose
incidence increases steeply with age (Lang and Lozano, 1998). It
is characterized by bradykinesia, resting tremor,muscular rigidity,
and postural instability. Although approximately less than 20% of
cases follow clear Mendelian inheritance and the majority of PD
is sporadic (Lees et al., 2009), there are 16 PD loci reported and at
least eight genes identiﬁed to date (Hardy et al., 2009).
Paroxysmal kinesigenic dyskinesias (PKD), also called parox-
ysmal kinesigenic choreoathetosis (PKC), is the most common
paroxysmal movement disorder and is characterized by recurrent,
brief attacks of dyskinesia that are induced by sudden voluntary
movements. The attacks manifest in dystonia or choreoathetosis.
There are two other types of paroxysmal dyskinesias: exercise-
induced (PED) and non-kinesigenic (PNKD). PED is genetically
heterogeneous and only a small percentage of familial and spo-
radic cases are explained by deﬁciency in the glucose transporter
type 1 gene (GLUT1) whereas PNKD ismainly due tomutations in
themyoﬁbrillogenesis regulator 1 gene (MR-1; Bhatia, 2011).Most
PKD cases follow an autosomal dominant (AD) inheritance pat-
tern (65–72%). Benign familial infantile epilepsy (BFIE) clinically
resembles PKD and thus both are often misdiagnosed. BFIE can
be familial or sporadic and is characterized by brief, non-febrile
convulsions starting in the ﬁrst year of life (Rochette et al., 2008).
The co-occurrence of BFIE and PKD within a single family gave
rise to the distinct clinical entity called infantile convulsions and
choreoathetosis (ICCA) syndrome.
Spastic paraplegias are a group of MDs characterized by pro-
gressive spasticity in the lower limbs. Clinically they are classiﬁed
as pure when consisting mainly of spasticity, abnormal reﬂexes,
and motor deﬁcits, or complex when a wide range of neurolog-
ical symptoms are also present (Salinas et al., 2008). Genetically,
they can arise from mutations in at least 23 genes, with more
still being discovered, as 48 SPG loci have already been reported.
Spasticity is also a symptom often seen in many other neurologi-
cal diseases, and mutations in some SPG genes are responsible for
other neurodegenerative diseases such as atypical ALS and atypical
Parkinsonism (Orlacchio et al., 2010; Paisan-Ruiz et al., 2010).
Tourette syndrome/chronic tic disorder (TS–CTD) is fairly com-
mon, affecting 1–10 per 1000 boys, with milder versions affecting
up to 10%of children (Rampello et al., 2006). It is characterized by
motor and vocal tics. Although multiple rare copy number vari-
ants within several genes have recently been found associated with
TS (Sundaram et al., 2010), most of the genetic causes have yet to
be determined, as candidate gene association and linkage studies
have been inconsistent and irreproducible (Rampello et al., 2006).
As stated above and the literature illustrates, MDs are both
genetically and phenotypically heterogeneous and thus NGS tech-
nologies are the preferred and more rapid method to elucidate
their causal alleles.
NOVEL MOVEMENT DISORDER GENES IDENTIFIED THROUGH
NGS
In the last 2 years,NGS technologies have seen great use in the ﬁeld
of movement disorder genetics in which eight novel genes have
been elucidated and many other NGS-related manuscripts will
probably come to light in the next couple of years.Novel genes have
been identiﬁed for ALS, CMT type 2, PD, PKD, spinocerebellar
ataxia, BFIE, ICCA syndrome, and TS–CTD (Table 1A).
In some studies linkage analyses were carried out prior to NGS
approaches. For instance, several studies identiﬁed the chromo-
some 9p21 as a causal locus for both ALS and FTD (Le Ber et al.,
2009; Van Es et al., 2009; Shatunov et al., 2010). Although a large
Swedish family was previously reported as presenting with mainly
dementia in the ﬁrst to third generation andmotor neuron disease
and mild dementia in the fourth generation (Gunnarsson et al.,
1991), not until lately has the genetic cause for this link been iden-
tiﬁed: a massively expanded hexanucleotide repeat (GGGGCC).
This hexanucleotide repeat was found in a non-coding region
of C9orf72 located on chromosome 9p21 and is suggested to be
the most common cause of both FALS and FTD identiﬁed to
date (DeJesus-Hernandez et al., 2011; Renton et al., 2011). The
C9orf72-associated phenotype has recently been deﬁned as an
early-onset, AD neurodegenerative disease presenting with cog-
nitive and behavioral impairment, speciﬁc neuroimaging changes,
and reduced survival (Byrne et al., 2012). Similarly, PKD families
were previously linked to chromosome 16p.11–q12.1 by different
groups (Tomita et al., 1999), but not until now, taking advantage of
ES technologies, has the causal gene,PRRT2, been identiﬁed (Chen
et al., 2011; Wang et al., 2011; Li et al., 2012). PRRT2 mutations
have additionally been reported in BFIE and ICCA families pre-
viously linked to chromosome 16p.11–q12.1 (Szepetowski et al.,
1997; Caraballo et al., 2001; Heron et al., 2012), and in familial
and sporadic cases with PKD, ICCA, PED, or PNKD-like disease
(Liu et al., 2012), further conﬁrming the PRRT2’s pathogenic role.
TGM6 genetic variability has likewise identiﬁed in spinocerebellar
ataxia-35 (SCA35), which was mapped to chromosome 20p13-
12.2 and is characterized by a slowly progressive and relatively
pure form of adult-onset cerebellar ataxia affecting both upper
and lower limbs (Wang et al., 2010). TGM6, encoding transgluta-
minase 6, is expressed in Purkinje cells (Hadjivassiliou et al., 2008)
and anti-transglutaminase 6 antibodies have been proved to cause
ataxia in mice (Boscolo et al., 2010).
In conclusion, the pathogenesis of C9orf72, PRRT2, and TGM6
genes is fully disclosed by the linkage and disease-segregation data,
the absence of pathogenic mutations in neurologically normal
individuals, and their further replication in additional or animal
studies.
But other studies performed ES directly or after exclusion of
known genes. For instance,DYNC1H1 (cytoplasmic dynein heavy
chain 1) genetic variability, which was previously shown to cause
sensory neuropathy with motor neuron loss in mice (Chen et al.,
2007), has recently found responsible for AD CMT2 in humans
(Weedon et al., 2011). In addition, a mutation in the vacuo-
lar protein sorting 35 (VPS35), p.Asp620Asn, identiﬁed by two
independent groups in PD patients (Vilarino-Guell et al., 2011;
Zimprich et al., 2011), has both been replicated and failed to be
replicated in recent studies (Sheerin et al., 2011; Guella et al.,
www.frontiersin.org May 2012 | Volume 3 | Article 75 | 3
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2012); and even though disease-segregating mutations in three
genes, MRPL3, DNAJC13, and OFCC1, have recently identiﬁed in
a three-generational TS–CTD pedigree (Sundaram et al., 2011),
further studies are needed to corroborate this ﬁnding.
MOVEMENT DISORDER GENES ASSOCIATED WITH
MULTIPLE PHENOTYPES
With the advent of NGS technologies not only have novel MDs
genes been identiﬁed, but also 10 already-disease-associated genes
have been found mutated in other diseases, expanding the pheno-
typic spectrum associated with a single gene (Table 1B). In most
of these studies, SNPs-based arrays along with NGS were used
to identify the genetic defects underlying disease. Examples are
described below.
SPG11 mutation, although are known to be the most common
causes of autosomal recessive (AR) HSP with thin corpus callo-
sum(HSP-TCC;Hehr et al., 2007; Stevanin et al., 2007;Paisan-Ruiz
et al., 2008a), has also been identiﬁed in AR both parkinsonism
(Paisan-Ruiz et al., 2010) and juvenile ALS (ARJALS; Orlacchio
et al., 2010). Through the use of ES, this latter association has
recently been conﬁrmed (Daoud et al., 2012) in a family con-
sisting of two affected siblings, who one manifested with ALS and
the othermanifestedwithHSP-TCC, conﬁrming the intra-familial
phenotypic heterogeneity associated with SPG11 mutation, which
is also seen in recessively inherited parkinsonism (Anheim et al.,
2009). In conclusion, SPG11 genetic variability should be consid-
ered in SPG, ALS, and Parkinsonism, especially when they occur
within the same family (Figure 1). Likewise,FA2H mutationswere
ﬁrst known to cause complex forms of ARHSP (Edvardson et al.,
2008; Dick et al., 2010) and later to cause NBIA, a syndrome that
acquired the name of FAHN (Kruer et al., 2010). But recently, a
compound heterozygous FA2H mutation has also been identiﬁed
in a child with typical clinical features of NBIA and axonal sen-
sory neuropathy, conﬁrming previous ﬁndings and expanding the
phenotypic spectrum associated with FA2H genetic variability, as
axonal sensory neuropathy was not seen before in FAHN (Pier-
son et al., 2011b). KIF1A, already implicated in ID and autism
(Galasso et al., 2008), has recently found mutated in hereditary
sensory neuropathy type IIC (HSN2C; Riviere et al., 2011), non-
syndromic ID (NSID; Hamdan et al., 2011), and HSPs (Erlich
et al., 2011; Klebe et al., 2012). Due to their phenotypic hetero-
geneity,KIF1A mutations have been suggested to predict different
phenotypes depending on their nature: nonsense mutations lead
to a complete knockout of protein function and cause HSN2C
while missense mutations in the kinesin motor domain lead to
upper motor neuron dysfunction and cause SPG (Klebe et al.,
2012).
Previously, mutations in two subunits, AP4M1 and AP4E1,
of the adaptor protein complex 4 (AP4) were found associated
with AR spastic tetraplegia as well as cerebral palsy and micro-
cephaly, respectively (Verkerk et al., 2009; Moreno-De-Luca et al.,
2011). But recently, pathogenic mutations in three AP4 subunits,
AP4S1, AP4B1, and AP4E1, have also been identiﬁed in consan-
guineous families presentingwith early-onset complex SPG, severe
ID, microcephaly, inability to walk, and epilepsy (Abou Jamra
et al., 2011); AP4B1 pathogenic mutations are also responsible
for SPG type 47 (Bauer et al., 2012). Since patients carrying AP4
FIGURE 1 | Movement disorder genes associated with multiple
neurological phenotypes. Diseases and phenotypes are represented with
circles and ovals with genes involved shown between implicated diseases.
Dashed circles represent disorders in which more than one gene is
involved. Disease abbreviations are described in the main text.
mutations share many clinical features, the existence of a com-
plex AP4-deﬁciency syndrome, characterized by severe ID, growth
retardation, stereotypic laughter, progressive spasticity, cerebral
palsy, and inability to walk, has been suggested, further support-
ing the key role of AP4-mediated trafﬁcking in brain development
and functioning (Abou Jamra et al., 2011).
Mutations in AFG3L2, encoding a subunit of a mitochondrial
m-AAA protease, were previously associated with spinocerebel-
lar ataxia type 28 (SCA28; Di Bella et al., 2010), but recently, a
AFG3L2 mutation, p.Y616C, has also been identiﬁed in affected
siblings presenting with early-onset SPG, progressive myoclonic
epilepsy, and peripheral neuropathy (Pierson et al., 2011a), adding
peripheral neuropathy to theAFG3L2-associated symptoms. Since
AFG3L2 could form a homo-oligomeric isoenzyme with itself or
a hetero-oligomeric complex with paraplegin, whose mutations
are associated with an adult form of SPG (Casari et al., 1998),
the AFG3L2 mutation, p.Y616C, has been suggested to speciﬁ-
cally interrupt the formation of both the homo-oligomer and the
hetero-oligomer with paraplegin, giving rise to a complex phe-
notype that combines symptoms of SPG7 and SCA28 along with
mitochondrial symptoms like myoclonic epilepsy (Pierson et al.,
2011a).
SYT14, previously found mutated in a 12-year-old girl with
AD cerebral atrophy, macrocephaly, seizures, and developmen-
tal delay, in the form of a de novo balanced rearrangement
[t(1;3)(q32.2;q25.2; Quintero-Rivera et al., 2007)], has lately been
found mutated in AR forms of SCA (ARCA) and psychomotor
retardation (Doi et al., 2011). Although both cases present with
mental retardation and cerebellar atrophy, the ARCA phenotype
differs in the mode of inheritance and presents with oculomo-
tor apraxia, spasticity, peripheral neuropathy, retinal abnormality,
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and psychomotor retardation, largely increasing the phenotypic
spectrum associated with SYT14 genetic variability.
Likewise, disease-segregating mutations in the valosin-
containing protein, VCP, known to cause inclusion body myopa-
thy, Paget disease, and FTD (IBMPFD), have recently been iden-
tiﬁed in FALS (Johnson et al., 2010), suggesting that the motor
neuron degeneration seen in ALS patients should be included in
the IBMPF-associated phenotype. Indeed, the presence of both
Paget’s disease and FTD was subsequently reported in two ALS
families carrying VCP mutations (Johnson et al., 2010).
Mutations in the colony-stimulating factor 1 receptor, CSF1R,
previously implicated in tumor development, including myeloid
and hematological malignancies (Ridge et al., 1990), have recently
been identiﬁed in patients with HDLS, who reported having
no bone-structure abnormalities (Rademakers et al., 2011); this
suggests that CSF1R, which regulates the survival, proliferation,
differentiation, and function of microglia in the brain (Stan-
ley et al., 1997), may also be implicated in motor dysfunction.
Likewise, SLC16A2 genetic variability, which was already impli-
cated in X-linked mental retardation, Allan–Herndon–Dudley
syndrome, and Pelizaeus–Merzbacher-like disease (Friesema et al.,
2004; Dumitrescu et al., 2006; Frints et al., 2008; Vaurs-Barriere
et al., 2009), has recently been associated with a X-linked form
of leukoencephalopathy, clinically diagnosed as PMD (Tsurusaki
et al., 2011).Although SLC16A2 encodes a thyroid hormone trans-
porter known as monocarboxylate transporter 8, MCT8, none
of PMD patients carrying SLC16A2 mutations reported thyroid
dysfunction.
Lastly, mutations in GCDH, which encodes a glutaryl-CoA
dehydrogenase, were known to cause glutaric aciduria type 1
(GA-1; Busquets et al., 2000), which is characterized by accumula-
tion of glutaric acid (GA) and 3-hydroxyglutaric acid (3-OHGA)
in brain and body ﬂuids, leading to neurotoxicity, encephalopa-
thy, macrocephaly, and eventually a dystonic–dyskinetic disorder
(Jafari et al., 2011). However, a homozygous, disease-segregating
GCDH mutation has recently been identiﬁed in two siblings who
suffer from an AR progressive generalized dystonia (PGD; Marti-
Masso et al., 2012) and whose urine samples showed excess of
3-OHGA. Since neither patient showed encephalopathy ormacro-
cephaly, this ﬁnding associates GCDH deﬁciency with PGD, a
phenotype not previously described in GA-1-associated GCDH
deﬁciency.
DISCUSSION
Next-generation sequencing technologies enable a comprehensive
analysis of the entire genome and exome and as such have dramat-
ically progressed the ﬁeld of biological and biomedical research,
especially inMendeliandiseases.Nonetheless, these novelmethod-
ologies also have several limitations; for instance, although the
target coverage is continually improving, a complete coverage will
probably never be reached since speciﬁc genomic regions such
as GC-rich areas and repetitive elements are difﬁcult to amplify
and large copy number variations are hard to detect. Despite this,
here we report on several movements disorder studies in which
NGS technologies have successfully been employed for disease-
causing mutations’ identiﬁcation. Some of these ﬁndings have
already been replicated. This is the case of C9orf72 causing ALS
and PRRT2 causing PKD, ICCA syndrome, paroxysmal exercise-
induced dyskinesias, and paroxysmal non-kinesigenic dyskinesias.
In both cases, linkage analysis was performed years before the gene
identiﬁcation but the causal gene did not come to light until the
use of NGS technologies. As for C9orf72, since the genetic defect
is an expanded hexanucleotide repeat located in a non-coding
region, it would have been difﬁcult to ﬁnd through traditional gene
screening techniques, in which only coding variants are usually
examined. Two other novel MD genes identiﬁed, TGM6 caus-
ing cerebellar ataxia and DYNC1H1 causing CMT type 2, were
previously shown to cause similar symptoms inmice, further con-
ﬁrming their pathogenicity. Novel genes have also been identiﬁed
for PD and TS–CTD; but in contrast, due to the lack of both link-
age and functional data, further molecular studies are required to
further prove their pathogenicity.
These studies have demonstrated that ES is a terriﬁc tool tomol-
ecularly diagnose genetically and clinically heterogeneous MDs in
which a large number of genes should be screened and a wide
range of clinical features is usually present. In addition, recent
NGS studies have shown that a single gene may be involved in
multiple clinical entities. Accordingly, genes causing complex SPG
may also be responsible for ALS, cerebral palsy, FAHN, Parkin-
sonism, sensory neuropathy, and spinocerebellar ataxia pheno-
types; and VCP mutations already associated with IBMPFD, may
also be present in amyotrophic lateral sclerosis (Figure 1). These
phenotypic heterogeneities associated with a single gene clearly
lead us to seek the molecular events by which mutations in a
single gene can result in multiple phenotypes. This may lie in
the nature of the mutation, as suggested for KIF1A mutations
(Klebe et al., 2012), or the protein domain that is affected (De
Angelis et al., 1999). However, the fact that the same mutation
may sometimes cause multiple phenotypes requires the search
of additional factors implicated in the phenotypic expression of
a disease, such as interacting genes and other genetic and envi-
ronmental modiﬁers. To face this ambitious challenge, the char-
acterization of each gene function through cellular and animal
studies is crucial. Today, novel molecular targets and subsequent
cellular mechanisms may be determined by the employment of
high-throughput techniques using either small animals such as
Caenorhabditis elegans, Drosophila melanogaster, and Danio rerio,
or automated cell culturing. In addition, these throughput tech-
niques are perfect tools for drug discovery (Giacomotto and
Segalat, 2010; Jain et al., 2011). Taken together, these analyses will
deﬁnitely reveal novel insights into the disease-associated patho-
genesis, which in turn are essential for developing more effective
treatments.
We conclude that NGS, particularly in conjunction with other
methods like SNPs-based arrays, has the robust capability to iden-
tify disease-causing genes in a very limited time and to some
extent to expand the phenotypic spectrum associated with a sin-
gle gene, improving diagnosis and leading to the development of
more effective treatments. As NGS costs decrease, target coverage
increases, and ﬁltering databases grow, a trend toward sequenc-
ing the entire genome will come next, requiring advances in the
understanding of non-coding genetic events and in the identiﬁca-
tion of both genetic and environmental modiﬁers. Finally, our
understanding of the genetic contribution to MDs will surely
www.frontiersin.org May 2012 | Volume 3 | Article 75 | 7
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increase in the coming years, but further functional and cellu-
lar analyses will be required for establishing the disease-associated
mechanisms and building all molecular networks associated with
MDs.
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